ICUI · Icu Medical Inc/De · Financials

$161.08 -0.16 (-0.10%)

S&P 600 member Russell 2000 member Rebalance outlook locked

Customer concentration — top customer 19% of revenue

One customer — 19% of revenue (six months ended June 30, 2026)

“For the three and six months ended June 30, 2026, our consolidated worldwide net sales to a single distributor were 19%, and 19%, respectively, and for the three and six months ended June 30, 2025, were 19% and 18%.”

One customer — 19% of revenue (three months ended June 30, 2026)

“For the three and six months ended June 30, 2026, our consolidated worldwide net sales to a single distributor were 19%, and 19%, respectively, and for the three and six months ended June 30, 2025, were 19% and 18%.”

One customer — 19% of revenue (three months ended June 30, 2025)

“For the three and six months ended June 30, 2026, our consolidated worldwide net sales to a single distributor were 19%, and 19%, respectively, and for the three and six months ended June 30, 2025, were 19% and 18%.”

One customer — 18% of revenue (six months ended June 30, 2025)

“For the three and six months ended June 30, 2026, our consolidated worldwide net sales to a single distributor were 19%, and 19%, respectively, and for the three and six months ended June 30, 2025, were 19% and 18%.”

View the 10-Q filed Aug 6, 2026

Market Cap

$4.03B

25.01M

Volume · Oct 20 158.7K Avg daily vol (3M) 269.29K

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Pull these statements through the financial statements API or MCP →

Revenue

$2.23B -6.3%

FY2025

Net Income

$732K +100.6%

FY2025

Gross Margin

36.84% +2.2pp

FY2025

Operating Margin

1.92% +0.1pp

FY2025

Diluted EPS

$0.03 +100.6%

FY2025

Operating Cash Flow

$179.85M -11.9%

FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow Adjusted All Metrics

Annual Quarterly

Line Item	3Y	5Y	10Y	FY2026 (G)	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009	FY2008	FY2007
Revenue	-0.7%	+11.9%	+20.6%	—	$2.16B	$2.23B	$2.38B	$2.26B	$2.28B	$1.32B	$1.27B	$1.27B	$1.4B	$1.29B	$379.37M	$341.67M	$309.26M	$313.72M	$316.87M	$302.2M	$282.96M	$228.97M	$204.73M	$188.14M
Net Interest Income	—	—	—	—	—	-$83.03M	-$95.75M	-$95.22M	-$66.38M	$1.98M	$1.92M	—	—	—	—	—	—	—	—	—	—	—	—	—
Cost of Revenue	-3.8%	+11.7%	+24.2%	—	$1.31B	$1.41B	$1.56B	$1.52B	$1.58B	$824.82M	$809.51M	$794.34M	$830.01M	$866.52M	$177.97M	$160.87M	$157.86M	$158.98M	$160.36M	$159.84M	$153.99M	$122.7M	$114.91M	$109.9M
Gross Profit	+5.6%	+12.2%	+16.4%	—	$845.15M	$822.04M	$824.78M	$739.87M	$697.76M	$491.49M	$461.5M	$471.86M	$570.03M	$426.1M	$201.4M	$180.8M	$151.4M	$154.73M	$156.51M	$142.35M	$128.97M	$106.28M	$89.82M	$78.24M
Gross Margin	—	—	—	—	—	36.84%	34.62%	32.75%	30.6%	37.34%	36.31%	37.27%	40.72%	32.96%	53.09%	52.92%	48.96%	49.32%	49.39%	47.11%	45.58%	46.41%	43.87%	41.59%
Research & Development	-2.0%	+15.3%	+18.7%	—	$86.32M	$87.5M	$88.62M	$85.34M	$92.98M	$47.5M	$42.95M	$48.61M	$52.87M	$51.25M	$12.96M	$15.71M	$18.33M	$12.41M	$10.63M	$8.59M	$4.68M	$2.65M	$4.82M	$8.11M
Selling, General & Administrative	+0.9%	+17.1%	+22.3%	—	$615.07M	$625.21M	$638.76M	$606.69M	$608.35M	$302.58M	$283.95M	$276.98M	$320M	$302.17M	$89.43M	$83.22M	$88.94M	$89.01M	$84.6M	$85.29M	$76.64M	$68.21M	$53.61M	$45.48M
Amortization of Intangibles	-2.0%	+41.5%	+50.5%	—	$132.2M	$131.4M	$134.3M	$132.1M	$139.4M	$23.8M	$23.2M	$17.7M	$16.6M	$15M	$2.8M	$2.2M	$2.4M	$2.5M	$2.6M	$2.7M	$2.8M	$2.3M	—	—
Depreciation & Amortization	-5.1%	+18.6%	+27.2%	—	$201.27M	$200.74M	$219.51M	$228.77M	$235.15M	$89.7M	$85.63M	$76.92M	$74.74M	$66.57M	$19.05M	$18.07M	$19.45M	$19.51M	$19M	$18.29M	$17.35M	$15.67M	$14.22M	$11.8M
Restructuring Charges	-10.3%	+4.8%	—	—	—	—	—	$5.7M	$9.7M	-$1.8M	$7.9M	$8.4M	$4.5M	$18.8M	$800K	$6.7M	$3.5M	—	—	—	—	—	—	—
Total Operating Expenses	+1.7%	+16.5%	+21.4%	—	$773.09M	$779.21M	$781.82M	$717.05M	$740.66M	$368.25M	$363.34M	$364.5M	$540.27M	$439.39M	$118.46M	$112.23M	$112.36M	$102.78M	$95.23M	$77.13M	$81.31M	$70.85M	$58.43M	$53.6M
Operating Income	—	-15.3%	-4.6%	—	$72.06M	$42.83M	$42.96M	$22.83M	-$42.9M	$123.25M	$98.16M	$107.36M	$29.76M	-$13.29M	$82.94M	$68.57M	$39.04M	$51.95M	$61.28M	$65.22M	$47.66M	$35.43M	$31.38M	$24.65M
Operating Margin	—	—	—	—	—	1.92%	1.8%	1.01%	-1.88%	9.36%	7.72%	8.48%	2.13%	-1.03%	21.86%	20.07%	12.62%	16.56%	19.34%	21.58%	16.84%	15.47%	15.33%	13.1%
EBITDA	+8.2%	+5.8%	+10.9%	—	$273.33M	$243.57M	$262.48M	$251.6M	$192.25M	$212.94M	$183.79M	$184.28M	$104.49M	$53.28M	$101.99M	$86.64M	$58.48M	$71.46M	$80.28M	$83.52M	$65M	$51.1M	$45.6M	$36.44M
Interest Expense	+9.6%	+121.4%	+117.7%	—	$83M	$93.34M	$106.54M	$102.73M	$70.81M	$858K	$1.75M	$549K	$709K	$2.05M	$118K	$39K	—	—	—	—	—	—	—	—
Other Non-Operating Income	—	—	—	—	-$1.58M	-$232K	-$13.22M	-$5.91M	-$5.14M	-$2.04M	-$2.59M	$7.9M	-$6.67M	-$4.27M	$885K	$1.17M	$755K	$765K	$563K	$1.2M	$129K	$1.18M	$4.7M	$8.7M
Equity in Earnings of Unconsolidated Entities	—	—	—	—	-$1.62M	-$1.19M	$0	$0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Pretax Income	—	-46.3%	-24.2%	—	$754K	$4.36M	-$66.01M	-$78.3M	—	—	$97.49M	$114.71M	$22.37M	$51.28M	$85.16M	$69.7M	$39.79M	$52.71M	$61.84M	$66.42M	$47.79M	$36.61M	$36.08M	$33.35M
Income Tax	—	-25.5%	-20.7%	—	-$30.96M	$2.44M	$51.68M	-$48.64M	-$40.12M	$20.05M	$10.62M	$13.67M	-$6.42M	-$17.36M	$22.08M	$24.71M	$13.46M	$12.3M	$20.56M	$21.75M	$17.86M	$11.63M	$11.78M	$10.34M
Net Income	—	-61.5%	-33.8%	—	$30.09M	$732K	-$117.69M	-$29.66M	-$74.29M	$103.14M	$86.87M	$101.04M	$28.79M	$68.64M	$63.08M	$44.99M	$26.34M	$40.42M	$41.28M	$44.67M	$29.92M	$24.98M	$24.3M	$23.08M
Net Margin	—	—	—	—	—	0.03%	-4.94%	-1.31%	-3.26%	7.84%	6.83%	7.98%	2.06%	5.31%	16.63%	13.17%	8.52%	12.88%	13.03%	14.78%	10.58%	10.91%	11.87%	12.27%
Net Income Attributable to Noncontrolling Interests	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	$44.67M	$29.92M	$24.98M	—	-$70K
Comprehensive Income	—	+0.9%	+12.1%	—	$19.4M	$105.5M	-$204.01M	-$1.76M	-$136M	$85.39M	$100.75M	$102.58M	$26.81M	$74.96M	$62.57M	$33.78M	$14.59M	$44.04M	$43.09M	$42.5M	$27.67M	—	—	—
EPS (Basic) USD/shares	—	-62.7%	-36.6%	—	$1.21	$0.03	-$4.83	-$1.23	-$3.11	$4.86	$4.16	$4.90	$1.41	$3.50	$3.90	$2.84	$1.72	$2.75	$2.90	$3.23	$2.20	$1.70	$1.72	$1.62
EPS (Diluted) USD/shares	—	-62.5%	-36.3%	$8.60 – $9.00*	$1.19	$0.03^G	-$4.83^G	-$1.23^G	-$3.11^G	$4.74^G	$4.02^G	$4.69	$1.33	$3.29	$3.66	$2.73	$1.68	$2.65	$2.80	$3.15	$2.16	$1.67	$1.67	$1.51
Shares Outstanding (Basic Avg) shares	+1.1%	+3.3%	+4.5%	—	—	24.64M	24.39M	24.09M	23.87M	21.21M	20.91M	20.63M	20.39M	19.61M	16.17M	15.85M	15.28M	14.69M	14.22M	13.84M	13.61M	14.72M	14.14M	14.28M
Shares Outstanding (Diluted Avg) shares	+1.4%	+2.9%	+4.2%	—	—	24.9M	24.39M	24.09M	23.87M	21.78M	21.59M	21.55M	21.6M	20.86M	17.25M	16.5M	15.65M	15.27M	14.73M	14.16M	13.86M	14.98M	14.57M	15.27M

Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2007–FY2025: $226.68M in buybacks.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balance	As of	Amount	Source
Current debt and lease obligations	2026-06-30	USD 18,750,000	10-Q filed 2026-08-06
Current portion of long-term debt	2026-06-30	USD 18,750,000	10-Q filed 2026-08-06
Finance lease liabilities	2026-06-30	USD 6,101,000	10-Q filed 2026-08-06
Related accounting measures — not additional borrowing Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year. Current finance lease liabilities USD 2,357,000 Noncurrent finance lease liabilities USD 3,744,000
Noncurrent debt carrying amount	2026-06-30	USD 1,212,449,000	10-Q filed 2026-08-06
Operating lease liabilities	2026-06-30	USD 49,847,000	10-Q filed 2026-08-06
Related accounting measures — not additional borrowing Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year. Current operating lease liabilities USD 13,221,000 Noncurrent operating lease liabilities USD 36,626,000

Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue

2.30×

Peer median 3.22×

EV/EBIT

68.90×

Peer median 30.70×

P/E (TTM)

135.50×

Peer median 33.28×

EV/Adj. EBITDA (FY2026)

12.03×

Peer median 30.36×

Peer medians compare against the 24 similar-size Medical Instruments & Supplies companies (of 51 listed).

EV/Adj. EBITDA uses the company-stated “TTM Adjusted EBITDA”, extracted from the reconciliation in its SEC filings — the company's own non-GAAP definition, not an XBRL-tagged figure.

Valuation over time computed as of each quarter's filing date

EV/Adj. EBITDA uses the company-stated “TTM Adjusted EBITDA”, extracted from the reconciliation in its SEC filings as it existed at each sample date — the company's own non-GAAP definition, not an XBRL-tagged figure. Each point's tooltip names its TTM or fiscal-year basis.

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Geography (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
United States	$1,356,114,000	$1,532,104,000	$1,440,017,000	$1,460,069,000	$941,809,000	$910,627,000	$923,342,000	$1,054,681,000
EMEA	$411,684,000	$393,530,000	$373,571,000	$367,411,000	$147,488,000	$132,763,000	$130,530,000	$134,363,000
APAC Domain	$232,903,000	$232,820,000	$241,699,000	$257,208,000	$85,692,000	$79,610,000	—	—
Other Foreign Countries	$230,561,000	$223,592,000	$203,839,000	$195,309,000	$141,319,000	$148,004,000	$212,336,000	$210,996,000

By Product & Service (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Infusion Consumables	$1,109,130,000	$1,038,869,000	$969,129,000	$974,993,000	$555,189,000	$473,740,000	$477,611,000	$483,039,000
Infusion Systems	$684,208,000	$652,410,000	$629,043,000	$617,435,000	$352,321,000	$359,691,000	$328,282,000	$355,484,000
Vital Care	$437,924,000	$690,767,000	$660,954,000	$687,569,000	$408,798,000	$0	—	—
Critical Care	—	—	—	—	—	$48,602,000	$45,344,000	$53,532,000
Infusion Consumables Smiths Medical	—	—	—	—	—	$0	—	—
IV Solutions	—	—	—	—	—	$388,971,000	$414,971,000	$507,985,000
Vascular Access	—	—	—	—	—	$0	—	—

Key facts CIK 883984 CUSIP 44930G107 13F (30d) 25 filings 25 filers Visit website Investor relations